Home Cart Sign in  
Chemical Structure| 1206799-15-6 Chemical Structure| 1206799-15-6

Structure of Merestinib
CAS No.: 1206799-15-6

Chemical Structure| 1206799-15-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

LY2801653 is a potent and orally bioavailable inhibitor of c-MET kinase with Ki of 2 nM.

Synonyms: LY2801653

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Merestinib

CAS No. :1206799-15-6
Formula : C30H22F2N6O3
M.W : 552.53
SMILES Code : O=C(C1=CC=C(C)N(C2=CC=C(F)C=C2)C1=O)NC3=CC=C(OC4=CC5=C(N(C)N=C5)C=C4C6=CNN=C6)C(F)=C3
Synonyms :
LY2801653
MDL No. :MFCD23160048
InChI Key :QHADVLVFMKEIIP-UHFFFAOYSA-N
Pubchem ID :44603533

Safety of Merestinib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Merestinib

RTK

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
rSUM149 cells 100 nM and 1000 nM 24 h Merestinib significantly inhibited the pERK and peIF4E pathways in rSUM149 cells, reduced CDK1, XIAP, and SOD2 protein levels, and induced cell death. PMC11286775
SUM149 cells 100 nM and 1000 nM 24 h Merestinib significantly inhibited the pERK and peIF4E pathways in SUM149 cells, reduced CDK1, XIAP, and SOD2 protein levels. PMC11286775
U87 1 μM 1 h Merestinib blocked phosphorylation of eIF4E, indicating inhibition of MNK signaling. PMC5082426
83Mes 1 μM 1 h Merestinib blocked phosphorylation of eIF4E, indicating inhibition of MNK signaling. PMC5082426
GBM43 1 μM 1 h Merestinib blocked phosphorylation of eIF4E, indicating inhibition of MNK signaling. PMC5082426
U87 cells 1 μM 24 h Merestinib treatment resulted in a decrease in polysomal peak area, indicating inhibition of global protein synthesis. PMC5082426
83Mes cells 1 μM and 10 μM 24 h Merestinib treatment resulted in a decrease in polysomal peak area, indicating inhibition of global protein synthesis. PMC5082426
GBM43 cells 1 μM and 10 μM 24 h Merestinib treatment resulted in a decrease in polysomal peak area, indicating inhibition of global protein synthesis. PMC5082426
Ba/F3 cells 100 nM or 500 nM To evaluate the inhibitory effect of Merestinib at different concentrations on resistant clones of Ba/F3 cells. PMC8828669

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice Intracranial xenograft GBM model Oral 12 mg/kg Twice daily for 2 weeks Merestinib significantly prolonged survival and inhibited MNK signaling. PMC5082426
Nude mice Intracranial xenograft GBM model Oral 12 mg/kg Twice daily for 2 weeks Merestinib significantly prolonged survival in nude mice and inhibited tumor growth. PMC5082426
SHO mice TPR-MET mutant Ba/F3 cell xenograft model oral gavage 24 mg/kg once daily for 18 days To evaluate the tumor growth inhibitory effect of Merestinib in combination with Capmatinib on TPR-MET mutant Ba/F3 cell xenograft model. The combination treatment significantly reduced tumor growth. PMC8828669

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02370485 Healthy PHASE1 COMPLETED 2025-05-15 Covance, Daytona Beach, Florid... More >>a, 32117, United States Less <<
NCT02779738 Healthy PHASE1 COMPLETED 2025-08-16 Covance Clinical Research Inc,... More >> Daytona Beach, Florida, 32117, United States Less <<
NCT02920996 Carcinoma, Non-Small-Cell Lung... More >>|Solid Tumor Less << PHASE2 TERMINATED 2025-10-23 Massachusetts General Hospital... More >>, Boston, Massachusetts, 02114, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02115, United States Less <<
NCT03292536 Bone Metastases|Breast Cancer PHASE1 TERMINATED 2019-06-24 Huntsman Cancer Institute, Sal... More >>t Lake City, Utah, 84112, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.81mL

0.36mL

0.18mL

9.05mL

1.81mL

0.90mL

18.10mL

3.62mL

1.81mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories